Showing posts with label Imaging. Show all posts
Showing posts with label Imaging. Show all posts

Wednesday, January 6, 2010

Radiation overexposure from CT scans may be more widespread than previously estimated

Moral of the story: Again, watch out for those CT settings.

Source: AMA Morning Rounds 12/15/09

Radiation overexposure from CT scans may be more widespread than previously estimated.


The CBS Evening News (12/14, story 3, 2:20, Lapook) reported, "The problem of too much radiation during CT scans may be more widespread than anyone thought." In fact, "new research...found a wide variation in radiation dose for the most common CT scan like abdomen, pelvis, and chest. A survey of four hospitals found some patients received 13 times more radiation than others for the same type of scan."
        NBC Nightly News (12/14, story 8, 2:10, Bazell) reported, "Depending on the part of the body being scanned, each CT exposes a patient to an amount of radiation equal to between 30 and 440 chest X-rays." But, in a separate study, "researchers calculated that 72 million CT scans are performed in this country a year and concluded that could lead to 29,000 excess cancers and 15,000 excess deaths a year in the future."
        In that study, published in the Archives of Internal Medicine, researchers at the National Cancer Institute "found that people may be exposed to up to four times as much radiation as estimated by earlier studies," USA Today (12/15, Szabo) reports.
        Meanwhile, the second study, appearing in the same journal, of over 1,000 patients at four hospitals, showed that one woman out of 270 and one man out of 600 would suffer from cancer after undergoing a single heart scan at age 40, the Wall Street Journal (12/15, A3, Wang) reports. Researchers noted that the differences in radiation doses may be due to a lack of standardized settings and disparities in technology use.
        The Los Angeles Times (12/15, Maugh) reports that, in an accompanying editorial, Dr. Rita F. Redberg, editor of the journal, noted that "the articles...make clear that there is far more radiation from medical CT scans than has been recognized previously." Redberg said, "Even many otherwise healthy patients are being subjected to the radiation...because emergency [departments] are often sending patients to the CT scanner before they see a doctor."
        Bloomberg News (12/15, Ostrow) reports that in the National Cancer Institute study, "the authors predicted that lung cancer will be the most common radiation-related cancer followed by colon cancer and leukemia." For its part, the FDA "issued interim regulations Dec. 7 requiring closer monitoring of CT scans after more than 250 cases of exposure to excess radiation were reported since October."
        WebMD (12/14, Doheny), MedPage Today (12/14, Neale), NPR (12/15), Modern Healthcare (12/15, Rhea), HealthDay (12/14, Pallarito), and Reuters (12/15, Steenhuysen) also covered the story.

FDA investigates 300 radiation overdoses from CT scans.

Moral of the story: Just something to be aware of.  The CT might not be set correctly.

Source: AMA Morning Rounds 12/16/09

FDA investigates 300 radiation overdoses from CT scans.


NPR's (12/15, Neighmond) All Things Considered reported, "More than 300 patients may have received an overdose of radiation from a special type of CT scan used to image the brain. The Food and Drug Administration says the radiation overdoses occurred at three hospitals in Los Angeles County and one hospital in Huntsville, AL. FDA officials say there could be many more cases at hospitals nationwide as their investigation unfolds." Dr. Jeffrey Shuren, "acting director of the FDA's Center for Devices and Radiological Health," explained that "a regular CT scan to the brain is the equivalent of about 100 chest X-rays," whereas "a perfusion CT scan of the brain is equal to several hundred chest x-rays. Patients at the four hospitals who received excess radiation were exposed to the equivalent of several thousand X-rays instead -- three to eight times the expected radiation dose."

New, Higher Cancer Risk Estimates for CR Scans

Moral of the story: CT scans are being reevaluated for their cancer risk, which was underestimated in the past based on theoretical values and not actual practice data.

Source: ACP Internist Weekly 12/21/09

New estimates on cancer risk of CT scans
Two new studies warn of the cancer risk posed by CT scans and suggest some risk-reduction strategies.
A retrospective cross-sectional study calculated the radiation doses delivered by computed tomography (CT) scans performed at four different California hospitals. Doses ranged from 2 millisieverts (mSv) for a routine head CT to 31 mSv for a multiphase abdomen and pelvis scan. Many of the scans provided more radiation than is usually assumed to be the case; the median dose for a routine abdomen and pelvis scan was 66% higher than the expected 8 to 10 mSv. Even within each type of study, the effective dose varied significantly within and among the hospitals. There was a mean 13-fold variation between the highest and lowest doses for each procedure.
Extrapolating from these data, researchers calculated cancer risks, such that 1 in 270 women who underwent CT coronary angiography at age 40 would develop cancer from the scan. Risks were lower for men than women, and higher for younger than older patients (20-year-olds faced double the risk, 60-year-olds only half). The study was published in the Dec. 14/28 Archives of Internal Medicine.
Another study in the same issue used risk models to calculate how many cancers could eventually be attributed to CTs based on current scanning rates. Overall, they estimated that 29,000 future cancers could be caused by CT scans performed in the U.S. in 2007. Scans of the abdomen and pelvis contributed the most to the tally, and one-third of the cancers would be due to scans performed on patients between the ages of 35 and 54.
The authors of the studies and an accompanying editorial offered a number of solutions to this problem, including standardized protocols (such as have been applied to mammography), fewer multiple series examinations, dose reduction and registration, and greater use of American College of Radiology accreditation and criteria. The experts also called for a reduction in the number of inappropriate and unnecessary CT scans.

Tuesday, January 5, 2010

Bedside exam may be superior to CT in detecting post-brain surgery complications.

Moral of the story: CT is shown yet again to be less effective than originally thought, but will likely to continue to be gold standard because of litigation and societal desire for technology

Source: AMA Morning Rounds 12/29/09


Bedside exam may be superior to CT in detecting post-brain surgery complications.


HealthDay (12/28, Dotinga) reported that, according to a study appearing online in the Journal of Neurosurgery, "the low-cost, simple, but elegant neurological exam appears to be superior to a routine CT scan in determining return to the operating room" due to "post-brain surgery complications." A review of "the medical records of 251 patients who underwent CT scans within 24 hours of surgery" revealed that "the scans failed to show who would need to go back to the operating room." But, bedside exams showed "serious problems in 10 cases that required urgent CT scans; three of the patients needed to go back to the operating room."

Thursday, February 5, 2009

Breast cancer risk rapidly drops after stopping hormone therapy

Moral of the story: hormone replacement therapy is a better predictor of breast cancer incidence than mammography frequency. If you are on homone replacement therapy, get those mammo's! Both the Reuters article and NEJM journal abstract are included below.

Breast cancer risk rapidly drops after stopping hormone therapy
By Reuters Health
February 5, 2009


NEW YORK (Reuters Health), Feb 5 - The elevated risk of breast cancer seen with combined hormone therapy quickly declines after this treatment is stopped, according to a report in the New England Journal of Medicine for February 5.

The results of the Women's Health Initiative (WHI) trial released in 2002 linked use of estrogen plus progestin with increased breast cancer risk in postmenopausal women. Subsequently, use of this therapy in the U.S. decreased substantially accompanied by a drop in breast cancer rates. Whether the two trends were causally related, however, was unclear.

In fact, it was suspected that changes in the frequency of mammographic screening may have accounted for the apparent drop in breast cancer incidence.

To investigate, Dr. Marcia Stefanick, from Stanford University School of Medicine, California, and colleagues analyzed follow-up data from the WHI trial. Included in the postintervention phase of the trial were 7,854 women who had received conjugated equine estrogens (0.625 mg) plus medroxyprogesterone (2.5 mg) daily and 7,533 given placebo.

In the two years prior to the intervention phase of the study, fewer breast cancer diagnoses were seen in the combined hormone therapy group than in the placebo group. During the 5.6 years of intervention, however, the risk of breast cancer was 26% higher in the hormone therapy group.

After stopping hormone therapy, the risk of breast cancer fell rapidly. The annualized incidence decreased 43% within one year, and by two years it was essentially the same as in the placebo group.

Moreover, during this period, "differences in the frequency of mammography between the two groups were unchanged."

Overall, "This is very strong evidence that estrogen plus progestin causes breast cancer," Stefanick said in a statement. "You start women on hormones and within five years, their risk for breast cancer is clearly elevated. You stop the hormones and within one year, their risk is essentially back to normal. It's reasonably convincing cause-and-effect data."

Last Updated: 2009-02-04 17:00:12 -0400 (Reuters Health)

Related Reading

Current HRT use is associated with low-grade breast cancer tumors, October 22, 2008


N Engl J Med 2009;360:573-587

NEJM -- Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

NEJM -- Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Rowan T. Chlebowski, M.D., Ph.D., Lewis H. Kuller, M.D., Dr.P.H., Ross L. Prentice, Ph.D., Marcia L. Stefanick, Ph.D., JoAnn E. Manson, M.D., Dr.P.H., Margery Gass, M.D., Aaron K. Aragaki, M.S., Judith K. Ockene, Ph.D., Dorothy S. Lane, M.D., Gloria E. Sarto, M.D., Aleksandar Rajkovic, M.D., Ph.D., Robert Schenken, M.D., Susan L. Hendrix, D.O., Peter M. Ravdin, M.D., Ph.D., Thomas E. Rohan, M.B., B.S., Ph.D., Shagufta Yasmeen, M.D., Garnet Anderson, Ph.D., for the WHI Investigators


ABSTRACT

Background Following the release of the 2002 report of the Women's Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy in the United States decreased substantially. Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer. However, the cause of this decrease remains controversial.

Methods We analyzed the results of the WHI randomized clinical trial — in which one study group received 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily and another group received placebo — and examined temporal trends in breast-cancer diagnoses in the WHI observational-study cohort. Risk factors for breast cancer, frequency of mammography, and time-specific incidence of breast cancer were assessed in relation to combined hormone use.

Results In the clinical trial, there were fewer breast-cancer diagnoses in the group receiving estrogen plus progestin than in the placebo group in the initial 2 years of the study, but the number of diagnoses increased over the course of the 5.6-year intervention period. The elevated risk decreased rapidly after both groups stopped taking the study pills, despite a similar frequency of mammography. In the observational study, the incidence of breast cancer was initially about two times as high in the group receiving menopausal hormones as in the placebo group, but this difference in incidence decreased rapidly in about 2 years, coinciding with year-to-year reductions in combined hormone use. During this period, differences in the frequency of mammography between the two groups were unchanged.

Conclusions The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography.